Hershey s stock rallies after earnings beat, as chocolate sales jump We are off to a strong start and remain on track to deliver our business strategies and financial commitments for the year,.
Novo Nordisk s net profit soared by 51 percent in 2023 to 83.7 billion kroner ($12.1 billion) as sales of diabetes medication Ozempic and obesity drug Wegovy have boomed.
Ozempic maker Novo Nordisk and Mounjaro maker Eli Lilly dominate the lucrative weight loss drug market with Wegovy and Zepbound, but companies are racing to compete in one of the most lucrative markets in the history of the pharmaceutical industry.
Eli Lilly plans to launch its obesity drug, tirzepatide, in India next year. The drug, also known as Mounjaro for diabetes and Zepbound for weight-loss in the U.S., may see authorized generic versions. CEO David Ricks emphasized the need for India to enhance patent protection and eliminate redundant policies to attract global drugmaker investments.